Results 141 to 150 of about 34,947 (279)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States (SMILE)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world associations between semaglutide 2.4 mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity. Methods This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016–2024). Adults with obesity or with
Aleksandrina Ruseva, Wojciech Michalak, Matthew Bassan, Ella Xiaoyan Du, Anthony Fabricatore, Bríain Ó Hartaigh, Theo Man, Ramya Ramasubramanian, Pangsibo Shen, Jinlin Song, Zhenxiang Zhao, Francisco Lopez‐Jimenez   +11 more
wiley   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists

iNew Medicine, EarlyView.
Chao Xue
wiley   +1 more source

Prediction of incident heart failure in type 2 diabetes mellitus: Rationale and design of the DM‐HEART study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Preclinical heart failure (HF) (stages A and B) is common but easily overlooked in asymptomatic patients with type 2 diabetes (T2D). There is a paucity of evidence regarding how coexisting risk factors contribute to the development of HF in asymptomatic Asian patients with T2D, and there is a lack of guidance on the early identification of ...
Jiun‐Lu Lin, Yen‐Wen Wu, Sung‐Chen Liu, Chung‐Ming Tu, Heng‐Hsu Lin, Yi‐Fu Lin, Hao‐Yun Chang, Ming‐Nan Chien, Chih‐Yuan Wang, Chung‐Lieh Hung   +9 more
wiley   +1 more source

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis

Cardiovascular Diabetology
Background Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent clinical syndrome with high morbidity and mortality. Although HFpEF frequently coexists with cardiometabolic diseases, the causal mechanisms and potential ...
Mingzhi Lin, Jiuqi Guo, Hongqian Tao, Zhilin Gu, Wenyi Tang, Fuliang Zhou, Yanling Jiang, Ruyi Zhang, Dalin Jia, Yingxian Sun, Pengyu Jia   +10 more
doaj   +1 more source

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

Nocturnal Hypoxemic Burden Predicts Mortality in Patients Awaiting Heart Transplantation

Journal of Sleep Research, EarlyView.
Trial design and results on hypoxemic burden in the context of heart transplantation. ABSTRACT Risk stratification for patients with end‐stage heart failure (HF) awaiting heart transplantation (HTX) is crucial. Sleep‐disordered breathing (SDB) is a prevalent comorbidity, yet the impact of its resultant hypoxemic burden remains unclear in this ...
Max Potratz, Tatevik Manukyan, René Schramm, Angelika Costard‐Jäckle, Uwe Fuchs, Michiel Morshuis, Sabina P. W. Guenther, Sebastian V. Rojas, Volker Rudolph, Jan F. Gummert, Henrik Fox   +10 more
wiley   +1 more source

Real‐World Treatment of Patients With Sinus Node Dysfunction and Heart Failure With Preserved Ejection Fraction

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background Permanent pacemaker (PPM) implantation is recommended in patients with sinus node dysfunction (SND). In patients with coexisting heart failure with preserved ejection fraction (HFpEF), clinicians may be hesitant to treat SND due to concerns about exacerbating heart failure.
Nicole Habel, Sarah Rosemas, Lucas Higuera, Patrick Zimmerman, Markus Meyer   +4 more
wiley   +1 more source